NURR1 Agonists for Parkinson's Disease

Migration, Crosslink

📖

NURR1 Agonists for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-nurr1-agonists-parkins

📖 Wiki Page

therapeutic1431 wordssynced 2026-04-02

NURR1 Agonists for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NURR1 Agonists for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Target Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TH</td>
<td>Dopamine synthesis</td>
</tr>
<tr>
<td class="label">DDC (AADC)</td>
<td>Dopamine production</td>
</tr>
<tr>
<td class="label">SLC18A2 (VMAT2)</td>
<td>Dopamine storage</td>
</tr>
<tr>
<td class="label">SLC6A3 (DAT)</td>
<td>Dopamine reuptake</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Neurotrophic support</td>
</tr>
<tr>
<td class="label">BCL2</td>
<td>Anti-apoptotic</td>
</tr>
<tr>
<td class="label">PGC-1α (PPARGC1A)</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TH</td>
<td>Dopamine synthesis</td>
</tr>
<tr>
<td class="label">AADC</td>
<td>Dopamine production</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Neurotrophic support</td>
</tr>
<tr>
<td class="label">Bcl-2</td>
<td>Anti-apoptotic</td>
</tr>
<tr>
<td class="label">PGC-1α</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Nrf2</td>
<td>Antioxidant response</td>
</tr>
<tr>
<td class="label">IL-10</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Current Approach</td>
<td>Limitation</td>
</tr>
<tr>
<td class

...

NURR1 Agonists for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NURR1 Agonists for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Target Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TH</td>
<td>Dopamine synthesis</td>
</tr>
<tr>
<td class="label">DDC (AADC)</td>
<td>Dopamine production</td>
</tr>
<tr>
<td class="label">SLC18A2 (VMAT2)</td>
<td>Dopamine storage</td>
</tr>
<tr>
<td class="label">SLC6A3 (DAT)</td>
<td>Dopamine reuptake</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Neurotrophic support</td>
</tr>
<tr>
<td class="label">BCL2</td>
<td>Anti-apoptotic</td>
</tr>
<tr>
<td class="label">PGC-1α (PPARGC1A)</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TH</td>
<td>Dopamine synthesis</td>
</tr>
<tr>
<td class="label">AADC</td>
<td>Dopamine production</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Neurotrophic support</td>
</tr>
<tr>
<td class="label">Bcl-2</td>
<td>Anti-apoptotic</td>
</tr>
<tr>
<td class="label">PGC-1α</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Nrf2</td>
<td>Antioxidant response</td>
</tr>
<tr>
<td class="label">IL-10</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Current Approach</td>
<td>Limitation</td>
</tr>
<tr>
<td class="label">L-DOPA</td>
<td>Does not protect neurons</td>
</tr>
<tr>
<td class="label">Dopamine agonists</td>
<td>Symptomatic only</td>
</tr>
<tr>
<td class="label">Deep brain stimulation</td>
<td>Invasive, symptomatic</td>
</tr>
<tr>
<td class="label">GDNF</td>
<td>Delivery challenges</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">SKL-NR1 (CINT1)</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">8-MOP</td>
<td>FDA-approved</td>
</tr>
<tr>
<td class="label">Synthetic analogs</td>
<td>Pharma</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Primary Use</td>
</tr>
<tr>
<td class="label">8-MOP</td>
<td>Psoriasis/PUVA</td>
</tr>
<tr>
<td class="label">6-Mercaptopurine</td>
<td>Leukemia</td>
</tr>
<tr>
<td class="label">Fenretinide</td>
<td>Cancer trials</td>
</tr>
<tr>
<td class="label">Targretin (Bexarotene)</td>
<td>CTCL</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">AAV-NURR1</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">CINT1/SKL-NR1</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">8-MOP</td>
<td>Academic</td>
</tr>
</table>

NURR1 (Nuclear receptor related 1 protein, also known as NR4A2) is an orphan nuclear receptor essential for the development, maintenance, and function of [dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc). In [Parkinson's disease](/diseases/parkinsons-disease) (PD), NURR1 expression declines in the substantia nigra pars compacta, contributing to dopaminergic neuron vulnerability. NURR1 agonists represent a promising therapeutic strategy to enhance dopaminergic neuron survival and provide disease-modifying benefits.

Mermaid diagram (expand to render)

NURR1 Biology and Structure

Molecular Characterization

NURR1 is a member of the nuclear receptor superfamily (NR4A subfamily), including NUR77 (NR4A1) and NOR-1 (NR4A3). It lacks a conventional ligand-binding pocket and is classified as an orphan receptor.

Structural domains:

N-terminal domain: Contains AF-1 region for coactivator recruitment
DNA-binding domain: Two C4-type zinc fingers recognizing NurRE elements
Ligand-binding domain: Hydrophobic pocket targeted by agonists
C-terminal domain: Contains AF-2 region for transcriptional activation

Structural Insights

The NURR1 ligand-binding domain (LBD) contains a hydrophobic pocket that can be targeted by small molecule agonists. Key structural features:

H12 helix: Critical for AF-2 function and coactivator recruitment
Coactivator binding site: Accepts NR-box motifs from coactivator proteins
Dimerization interface: Forms heterodimers with RXR for DNA binding

Normal Physiological Functions

In dopaminergic neurons, NURR1 regulates:

Dopamine synthesis:

Tyrosine hydroxylase (TH): Rate-limiting enzyme in biosynthesis
Aromatic L-amino acid decarboxylase (AADC): Converts L-DOPA to dopamine
VMAT2 and DAT: Dopamine transport and reuptake

Neuronal survival:

Anti-apoptotic signaling through Bcl-2 family proteins
Neurotrophic factor support (BDNF)
Mitochondrial function maintenance

Gene regulatory network:

NURR1 in Parkinson's Disease Pathogenesis

Expression Deficits in PD

Multiple studies demonstrate NURR1 dysfunction:

Postmortem studies: NURR1 reduced by 40-60% in PD substantia nigra
Animal models: MPTP, 6-OHDA show NURR1 downregulation
Genetic associations: NURR1 polymorphisms linked to increased PD risk
Alpha-synuclein interaction: Pathogenic alpha-synuclein suppresses NURR1

Mechanisms of NURR1 Dysfunction

Transcriptional suppression:

α-Synuclein binds to NURR1 promoter, reducing transcription
Histone deacetylation at NURR1 locus
DNA methylation changes in PD brains

Post-translational modifications:

Reduced phosphorylation at activating sites
Increased sumoylation leading to reduced activity
Proteasomal degradation of NURR1 protein

Protein-protein interactions:

Disrupted interaction with coactivators (p300/CBP)
Enhanced interaction with corepressors
Sequestration by pathological protein aggregates

Disease-Relevant Target Genes

Therapeutic Rationale for NURR1 Activation

Neuroprotective Mechanisms

Enhanced dopamine biosynthesis: Increased TH and AADC expression

Anti-apoptotic effects: Bcl-2 upregulation protects against cell death

Mitochondrial function: PGC-1α activation improves energy metabolism

Anti-inflammatory: Suppression of microglial activation

Neurotrophic support: BDNF expression promotes neuron survival

Disease-Modifying Potential

Unlike symptomatic treatments, NURR1 agonists offer disease-modifying potential:

Protecting remaining dopaminergic neurons
Enhancing function of surviving neurons
Potential for regeneration in early disease stages

Advantages Over Current Therapies

Drug Development Approaches

Direct NURR1 Agonists

Small molecule activators:

CINT1 (SKL-NR1): First-generation NURR1 activator with in vivo activity
8-MOP (8-Methoxypsoralen): FDA-approved compound with NURR1 agonist activity
Ambocryptin B: Natural product with NURR1 agonist activity
CLX-1: Second-generation NURR1-selective agonist

Development status:

Gene Therapy Approaches

AAV-NURR1: Delivers NURR1 coding sequence to dopaminergic neurons
AAV-NURR1 combined with AADC: Enhanced dopamine production
CRISPR activation: CRISPR-dCas9 system for NURR1 upregulation

Repurposing Opportunities

Preclinical Evidence

In Vitro Studies

Primary mesencephalic cultures: NURR1 agonists protect against MPTP toxicity
LUHMES neurons: Enhanced differentiation and survival
Patient iPSC-derived neurons: Rescue of disease phenotypes
SH-SY5Y cells: Protection against 6-OHDA and rotenone

In Vivo Evidence

MPTP mice: NURR1 overexpression protects dopaminergic neurons
6-OHDA rats: Improved behavioral outcomes
Alpha-synuclein transgenic mice: Reduced pathology and improved motor function
Parkin knockout mice: Rescue of dopaminergic degeneration

Mechanistic Studies

Neuroprotection mechanisms:

Activation of PI3K/Akt signaling pathway
Inhibition of JNK/p38 MAPK pro-death signaling
Upregulation of antioxidant enzymes via Nrf2
Suppression of microglial activation

Clinical Development Status

Current Pipeline

Clinical Trial Design Considerations

Patient selection:

Early-stage PD (Hoehn & Yahr 1-2)
Confirmed dopaminergic deficit on DAT imaging
No contraindications to study drug

Endpoints:

DAT PET imaging for target engagement
Motor symptoms (MDS-UPDRS)
Non-motor symptoms (嗅觉, sleep)
Biomarkers (CSF BDNF, inflammatory markers)

Challenges

Confirming CNS target engagement in humans
Developing biomarkers for NURR1 activation
Long-term safety considerations
Combination with standard of care

Combination Therapies

NURR1 agonists may be combined with:

Levodopa/carbidopa: Standard of care; potential synergistic effects
LRRK2 inhibitors: Complementary mechanisms (lysosomal function)
GBA substrate reducers: Address glucocerebrosidase deficiency
Monoamine oxidase-B inhibitors: Enhanced dopamine metabolism
Deep brain stimulation: Potential for enhanced motor outcomes

Biomarkers and Patient Selection

Potential Biomarkers

Blood NURR1 levels: Peripheral monocyte NURR1 expression
CSF BDNF: Downstream effect marker
DAT PET: Pre- and post-treatment imaging
Inflammatory markers: IL-6, TNF-α in blood/CSF

Patient Selection Criteria

Patients most likely to benefit:

Early-stage PD (Hoehn & Yahr 1-2)
NURR1 expression deficit on biopsy (if available)
Rapid disease progression
Family history (may have NURR1 variants)

Future Directions

Brain-penetrant compounds with improved pharmacokinetics
Combination with LRRK2 inhibitors
Biomarker development for clinical trials
Triple combinations addressing multiple pathways
Gene therapy optimization for AAV delivery

Conclusion

NURR1 agonists represent a promising disease-modifying approach for Parkinson's disease that addresses fundamental dopaminergic neuron vulnerability. By targeting a nuclear receptor regulating the entire dopaminergic phenotype, these agents offer potential for comprehensive neuroprotection and functional restoration.

References

[Jankovic et al., NURR1 in PD (2005)](https://doi.org/10.1136/jnnp.2004.044172)

[Kadkhodaei et al., NURR1 and PD (2009)](https://doi.org/10.1073/pnas.0907327106)

[Zhang et al., NURR1 agonists (2022)](https://doi.org/10.1002/mds.28014)

[Decressac et al., NURR1 as therapeutic target (2013)](https://doi.org/10.1016/j.neurobiolaging.2013.03.018)

[Rangel-Barajas et al., NURR1 and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/41727529)

[Zhang et al., NURR1 agonists in PD models (2021)](https://pubmed.ncbi.nlm.nih.gov/34119603)

[Kim et al., AAV-NURR1 gene therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32489714)

[Jochumsen et al., NURR1 and alpha-synuclein (2019)](https://pubmed.ncbi.nlm.nih.gov/30684217)

[Chen et al., NURR1 epigenetic regulation in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/31408200)

[Lewandowski et al., NURR1 and mitochondrial function (2020)](https://pubmed.ncbi.nlm.nih.gov/30121937)

[Södersten et al., NURR1-based therapies in PD (2014)](https://doi.org/10.1002/mds.25919)

[Yu et al., NURR1 and neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/38098012)

📖 View canonical wiki page →

Related Entities

therapeutics-nurr1-agonists-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-nurr1-agonists-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7f4f9fc9e6bb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-nurr1-agonists-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

87

Outgoing

92

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NURR1 Agonists for Parkinson's Disease

NURR1 Agonists for Parkinson's Disease

Overview

NURR1 Agonists for Parkinson's Disease

Overview

NURR1 Biology and Structure

Molecular Characterization

Structural Insights

Normal Physiological Functions

NURR1 in Parkinson's Disease Pathogenesis

Expression Deficits in PD

Mechanisms of NURR1 Dysfunction

Disease-Relevant Target Genes

Therapeutic Rationale for NURR1 Activation

Neuroprotective Mechanisms

Disease-Modifying Potential

Advantages Over Current Therapies

Drug Development Approaches

Direct NURR1 Agonists

Gene Therapy Approaches

Repurposing Opportunities

Preclinical Evidence

In Vitro Studies

In Vivo Evidence

Mechanistic Studies

Clinical Development Status

Current Pipeline

Clinical Trial Design Considerations

Challenges

Combination Therapies

Biomarkers and Patient Selection

Potential Biomarkers

Patient Selection Criteria

Future Directions

Conclusion

References

💬 Discussion